keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/29472362/open-label-multicentre-dose-escalating-phase-ii-clinical-trial-on-the-safety-and-efficacy-of-tadekinig-alfa-il-18bp-in-adult-onset-still-s-disease
#1
Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, Ina Kötter, Eric Hachulla, Jacques Morel, Thierry Schaeverbeke, Mohamed A Hamidou, Thierry Martin, Bernhard Hellmich, Peter Lamprecht, Hendrik Schulze-Koops, Delphine Sophie Courvoisier, Andrew Sleight, Eduardo Jorge Schiffrin
OBJECTIVES: Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. METHODS: In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs)...
February 22, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29470611/osteoporosis-in-rheumatic-diseases-anti-rheumatic-drugs-and-the-skeleton
#2
REVIEW
Alanna M Dubrovsky, Mie Jin Lim, Nancy E Lane
Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab...
February 22, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29466690/safety-and-efficacy-of-etanercept-methotrexate-combination-therapy-in-patients-with-rhupus-an-observational-study-of-non-glucocorticoid-treatment-for-rheumatic-diseases
#3
Bei-Bei Yang, Hua Xiao, Xiao-Jie Li, Min Zheng
OBJECTIVES: To evaluate the safety and efficacy of etanercept (ETN) plus methotrexate (MTX) in patients with rhupus without using corticosteroids. METHODS: Twenty rhupus patients [meeting the criteria for both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)] who had never been treated with corticosteroids, DMARDs, or biological agents with a 28-joint Disease Activity Score (DAS28) >3.2 and lupus nephritis determined from histopathological specimens were enrolled...
January 2018: Discovery Medicine
https://www.readbyqxmd.com/read/29464523/methotrexate-preferentially-affects-tc1-and-tc17-subset-of-cd8-t-lymphocytes
#4
Amit Sandhu, Shabeer Ahmad, Prabhdeep Kaur, Archana Bhatnagar, Veena Dhawan, Varun Dhir
Rheumatoid arthritis is considered a T-lymphocyte-mediated disease. However, studies have focussed on CD4 T-lymphocytes, ignoring CD8 T-lymphocytes despite the latter being found abundantly in the synovium. Specifically, there is little data of the effect of methotrexate, the gold-standard DMARD, on various CD8 cytokine T-lymphocyte subsets and conflicting data on CD4 subsets. In this prospective study, patients with active rheumatoid arthritis, who were 18 to 65 years of age, were treated with methotrexate (up to 25 mg per week) for 24 weeks...
February 20, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29464513/lipids-in-ra-is-less-not-necessarily-more
#5
REVIEW
Jorge Plutzky, Katherine P Liao
PURPOSE OF REVIEW: In rheumatoid arthritis (RA), lipid levels are dynamic and can fluctuate along with changes in inflammation. A reduction in inflammation, most commonly as a result of disease-modifying anti-rheumatic drug (DMARD) therapy, is associated with increases in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). In this review, we discuss new evidence shedding light on the potential mechanism underlying changes in lipid levels observed with changes in inflammation...
February 21, 2018: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29461957/disease-activity-and-dropout-in-young-persons-with-juvenile-idiopathic-arthritis-in-transition-of-care-a-longitudinal-observational-study
#6
Philomine A van Pelt, Radboud J E M Dolhain, Aike A Kruize, Judy J W Ammerlaan, Johanna W Hazes, Johannes W J Bijlsma, Nico M Wulffraat
OBJECTIVES: Reaching a certain age, juvenile idiopathic arthritis (JIA) patients in paediatric care are transferred to adult care. An increased disease activity after transfer and increased dropout has been suggested, however, evidence is scarce. Our aim is to determine whether the process of transition is associated with increased disease-activity and dropout, and to identify associated factors. METHODS: During a 3-year prospective transition cohort study, paediatric patients (14-17yrs) were transferred to adult care...
January 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29452300/therapeutic-strategy-for-rheumatoid-arthritis-patients-who-have-achieved-remission
#7
Bruno Fautrel
Once remission or low disease activity (LDA) is attained in established rheumatoid arthritis (RA) patients, attempting disease-modifying anti-rheumatic drug (DMARD) tapering appears to be a viable option to avoid patient overtreatment. Potential benefits include reduction in the treatment burden and the risk of adverse events, although the latter has not been demonstrated convincingly.The feasibility of DMARD discontinuation has been tested in numerous studies or trials. All have revealed a high risk of relapse, ranging from 56% to 87% at one year...
February 13, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29450976/high-adherence-observed-to-system-level-performance-measures-for-rheumatoid-arthritis-in-a-national-early-arthritis-cohort-over-8-years
#8
Claire E H Barber, Orit Schieir, Diane Lacaille, Deborah A Marshall, Cheryl Barnabe, Glen Hazlewood, Carter Thorne, Vandana Ahluwalia, Susan J Bartlett, Gilles Boire, Boulos Haraoui, Carol A Hitchon, Edward Keystone, Diane Tin, Janet Pope, Lisa Denning, Vivian Bykerk
OBJECTIVE: To assess adherence to three System-Level Performance Measures in a national early RA (ERA) cohort. METHODS: Patients enrolled in the Canadian Early Arthritis Cohort (2007-2015) who met 1987 or 2010 ACR/EULAR criteria with <1year of symptom duration and ≥1year of follow-up after enrollment were included. Performance measures assessed were: i) the percentage of RA patients seen in yearly follow-up, and number of gaps between visits of >12 or 14 months, ii) the percentage of RA patients treated with a disease-modifying drug (DMARD) and, iii) days from RA diagnosis to initiation of DMARD...
February 16, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29445863/use-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-in-austria-from-2008-to-2011-a-retrospective-analysis-of-72-of-the-population
#9
Tanja A Stamm, Berthold Reichardt, Jochen Zwerina, Valentin Ritschl, Valerie Nell-Duxneuner
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6...
February 14, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29415145/response-to-baricitinib-based-on-prior-biologic-use-in-patients-with-refractory-rheumatoid-arthritis
#10
Mark C Genovese, Joel M Kremer, Cynthia E Kartman, Douglas E Schlichting, Li Xie, Tara Carmack, Carlos Pantojas, Juan Sanchez Burson, Hans-Peter Tony, William L Macias, Terence P Rooney, Josef S Smolen
Objective: RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. Methods: RA-BEACON patients (previously reported) had moderate to severe RA with insufficient response to one or more TNF inhibitor and were randomized 1:1:1 to once-daily placebo or 2 or 4 mg baricitinib. Prior bDMARD use was allowed. The primary endpoint was a 20% improvement in ACR criteria (ACR20) at week 12 for 4 mg vs placebo...
February 3, 2018: Rheumatology
https://www.readbyqxmd.com/read/29391382/identification-of-new-biomarkers-to-promote-personalised-treatment-of-patients-with-inflammatory-rheumatic-disease-protocol-for-an-open-cohort-study
#11
Tina Marie Kringelbach, Bente Glintborg, Estrid V Hogdall, Julia Sidenius Johansen, Merete Lund Hetland
INTRODUCTION: The introduction of biological disease-modifying antirheumatic drugs (bDMARDs) has improved the treatment of inflammatory rheumatic diseases dramatically. However, bDMARD treatment failure occurs in 30%-40% of patients due to lack of effect or adverse events, and the tools to predict treatment outcomes in individual patients are currently limited. The objective of the present study is to identify diagnostic, prognostic and predictive biomarkers, which can be used to (1) diagnose inflammatory rheumatic diseases early in the disease course with high sensitivity and specificity, (2) improve prognostication or (3) predict and monitor treatment effectiveness and tolerability for the individual patient...
February 1, 2018: BMJ Open
https://www.readbyqxmd.com/read/29389829/therapeutic-drug-monitoring-of-biologicals-in-rheumatoid-arthritis-a-disconnect-between-beliefs-and-facts
#12
Alfons A den Broeder, Noortje van Herwaarden, Bart J F van den Bemt
PURPOSE OF REVIEW: To give an overview of recently published articles covering therapeutic drug monitoring (TDM) of biological DMARDs (bDMARDs) in rheumatoid arthritis. RECENT FINDINGS: In the last 18 months, two clinical studies and nine reviews were found after a systematic literature search. Most (narrative) reviews conclude that TDM should be used to improve biological treatment in rheumatoid arthritis patients, whereas most of the clinical studies (including 13 studies identified earlier) whenever scrutinized do not support this conclusion...
January 31, 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29378619/chromosome-conformation-signatures-define-predictive-markers-of-inadequate-response-to-methotrexate-in-early-rheumatoid-arthritis
#13
Claudio Carini, Ewan Hunter, Aroul S Ramadass, Jayne Green, Alexandre Akoulitchev, Iain B McInnes, Carl S Goodyear
BACKGROUND: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and, whether there is an association between such a signature and RA specific expression quantitative trait loci (eQTL)...
January 29, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29368023/variability-in-the-prescription-of-biological-drugs-in-rheumatoid-arthritis-in-spain-a-multilevel-analysis
#14
Francisco Javier López-Longo, Daniel Seoane-Mato, María A Martín-Martínez, Fernando Sánchez-Alonso
To describe variability in the prescription of biologics (B-DMARDs) for patients with rheumatoid arthritis (RA) in hospitals in Spain, and to explore which characteristics of the patient, the doctor and the hospital are associated with this variability. Cross-sectional multicentric study in 46 rheumatology services of the National Health System. Medical records of 1188 randomly selected patients were reviewed. The association of each variable with B-DMARD prescription was analyzed using simple logistic regressions...
January 24, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29365183/drug-immunogenicity-in-patients-with-inflammatory-arthritis-and-secondary-failure-to-tumour-necrosis-factor-inhibitor-therapies-the-reason-study
#15
Alejandro Balsa, Raimon Sanmarti, José Rosas, Victor Martin, Ana Cabez, Susana Gómez, María Montoro
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted...
January 19, 2018: Rheumatology
https://www.readbyqxmd.com/read/29361199/mavrilimumab-a-fully-human-granulocyte-macrophage-colony-stimulating-factor-receptor-%C3%AE-monoclonal-antibody-long-term-safety-and-efficacy-in-patients-with-rheumatoid-arthritis
#16
Gerd R Burmester, Iain B McInnes, Joel M Kremer, Pedro Miranda, Jiří Vencovský, Alex Godwood, Marius Albulescu, M Alex Michaels, Xiang Guo, David Close, Michael Weinblatt
OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte-macrophage colony-stimulating factor receptor alpha. We report mavrilimumab long-term safety and efficacy in rheumatoid arthritis patients in two phase IIb studies (1071, 1107) and open-label extension (OLE; NCT01712399). METHODS: In 1071, patients with disease-modifying antirheumatic drug (DMARD)-inadequate responses received mavrilimumab 30, 100, 150 mg, or placebo every other week (eow), plus methotrexate...
January 23, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29352841/predict-rheumatoid-arthritis-conversion-from-undifferentiated-arthritis-with-dynamic-contrast-enhanced-mri-and-laboratory-indexes
#17
Xinwei Lei, Huixia Li, Ying Zhan, Jin Qu
OBJECTIVES: To investigate the clinical value of dynamic contrast-enhanced MRI (DCE-MRI) and laboratory indexes in predicting conversion from undifferentiated arthritis (UA) to rheumatoid arthritis (RA). METHODS: A total 81 DMARD-naive UA patients were studied. 37 cases were ultimately diagnosed as RA, 32 cases were diagnosed as other types of arthritis, and the remaining cases were still UA during the 1-year follow-up. The DCE-MRI and laboratory measures were fed into a logistic regression analysis...
January 15, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29350637/clinical-utility-of-eco-color-power-doppler-ultrasonography-and-contrast-enhanced-magnetic-resonance-imaging-for-interpretation-and-quantification-of-joint-synovitis-a-review
#18
Marina Carotti, Vittoria Galeazzi, Francesca Catucci, Marcello Zappia, Francesco Arrigoni, Antonio Barile, Andrea Giovagnoni
With the introduction of new biologics such as anti-TNF-alpha antibodies and other therapies in the treatment of inflammatory arthritis, capable of halting joint destruction and functional disability, there are new pressures on diagnostic and prognostic imaging. Early demonstration of pre-erosive inflammatory features and monitoring of the long-term effects of treatment are becoming increasingly important. Early detection of synovitis offers advantages in terms of allowing early instigation of therapy and may allow the identification of those patients displaying more aggressive disease who might benefit from early intervention with expensive DMARD therapy...
January 19, 2018: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29346649/endothelial-function-in-rheumatoid-arthritis
#19
Mohammad Adawi, Abdulla Watad, Nicola Luigi Bragazzi, Howard Amital, Saaida Golan, Sirchan Rizak, Blum Arnon
Background: Rheumatoid arthritis (RA) patients are at higher risk of accelerated atherosclerosis. We sought to assess endothelial dysfunction in RA to find a possible mechanistic pathway that will explain this clinical phenomenon. Methods: A prospective study recruited 44 RA patients with an active long standing (>12 months) disease. All underwent a detailed assessment of disease activity. To estimate the endothelial function the Brachial Artery Method was performed, measuring flow mediated diameter percent change (FMD%)...
January 15, 2018: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/29336618/rheumatoid-arthritis-a-single-center-egyptian-experience
#20
B R Sakr, M M Elfishawi, M H ElArousy, A K Hatw, A N AbdulKarim, A B Tammam, A N Kotp, M E Hamed, I E Genedy, E D El Desouky, Z O Nawito
OBJECTIVE: Demonstration of rheumatoid arthritis (RA) characteristics in a large cohort of Egyptian patients. METHODS: Retrospective analysis of data of 3219 RA patients attending the Rheumatology outpatient clinic, Kasr Alainy Hospital, Cairo University; from January 1995 till December 2015. RESULTS: Mean age at disease onset was 36.1 ±13.4 years; 2774 (84%) were females and mean disease duration was 12.9 ±7.9 years. Regarding number of joint affected at disease onset; polyarticular pattern was found in 77...
January 16, 2018: Immunological Investigations
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"